Although the BEACON study showed a significant increase in eGFR by 5.5 mL/min/1.73 m 2 in the group treated with 20 mg/day CDDO-ME, this clinical trial was terminated in 2012 because of the high incidence of cardiovascular events, especially heart failure, in the group treated with CDDO-ME (Table 3) [16]
Therefore, the relatively low abundance of lipoylation in untreated cells suggests that lipoylation is rate-limiting for the OGDHc, and our findings are consistent with the accumulation of Lp glu following ABHD11 inhibition, which reduces OGDHc activity (Fig
The only long-term trial was discontinued due to a case of fatal myocardial infarction, deemed unrelated to CJC-1295 itself [9]
trial data do not describe product data
These peptides, which are marketed for a wide variety of health benefits and therapies, have largely been untested in humans
High-speed fixed-target serial virus crystallography